Reacción a "Both the drug orforglipron and a probiotic supplement help patients with obesity maintain their weight loss, according to two independent clinical trials "

This is a well-designed clinical trial evaluating two treatments aimed at addressing one of the main issues with incretin mimetics, such as semaglutide (Ozempic) and tirzepatide (Mounjaro): weight regain following discontinuation of treatment. This occurs particularly when patients have failed to maintain changes in lifestyle and diet, although weight regain can occur even with these modifications.

The study analyses the outcomes following treatment with both incretin mimetics and, once treatment has ended, the switch to oral orforglipron, administered once daily—an option that may facilitate treatment adherence. The results show that combination therapies represent a promising strategy for maintaining weight loss after discontinuing injectable treatments and improving treatment adherence. As seen in the results of the semaglutide trial, continuing with oral orforglipron appears even more effective than when used following tirzepatide.

Key limitations of the trial include the short duration of follow-up, the absence of a group continuing with injectable therapy for comparison purposes, and the limited diversity of the study population. Furthermore, the possibility of receiving rescue treatment has made it difficult to clearly interpret the differences compared with placebo.

Nevertheless, the findings are highly interesting and align with current evidence, which regards obesity as a chronic condition requiring long-term treatment and continuous monitoring. Overall, both trials support the development of combination and personalised therapies as a useful option for improving the comprehensive management of obesity and thereby enhancing treatment adherence.